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Abstract
Background: Neuroblastoma, a cancer derived from precursor cells of the sympathetic nervous system, is a major cause of
childhood cancer related deaths. The single most important prognostic indicator of poor clinical outcome in this disease is
genomic amplification of MYCN, a member of a family of oncogenic transcription factors.
Methodology: We applied MYCN chromatin immunoprecipitation to microarrays (ChIP-chip) using MYCN amplified/non-
amplified cell lines as well as a conditional knockdown cell line to determine the distribution of MYCN binding sites within
all annotated promoter regions.
Conclusion: Assessment of E-box usage within consistently positive MYCN binding sites revealed a predominance for the
CATGTG motif (p,0.0016), with significant enrichment of additional motifs CATTTG, CATCTG, CAACTG in the MYCN
amplified state. For cell lines over-expressing MYCN, gene ontology analysis revealed enrichment for the binding of MYCN
at promoter regions of numerous molecular functional groups including DNA helicases and mRNA transcriptional
regulation. In order to evaluate MYCN binding with respect to other genomic features, we determined the methylation
status of all annotated CpG islands and promoter sequences using methylated DNA immunoprecipitation (MeDIP). The
integration of MYCN ChIP-chip and MeDIP data revealed a highly significant positive correlation between MYCN binding
and DNA hypermethylation. This association was also detected in regions of hemizygous loss, indicating that the observed
association occurs on the same homologue. In summary, these findings suggest that MYCN binding occurs more commonly
at CATGTG as opposed to the classic CACGTG E-box motif, and that disease associated over expression of MYCN leads to
aberrant binding to additional weaker affinity E-box motifs in neuroblastoma. The co-localization of MYCN binding and DNA
hypermethylation further supports the dual role of MYCN, namely that of a classical transcription factor affecting the activity
of individual genes, and that of a mediator of global chromatin structure.
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Introduction
MYCN is one member of a family of oncogenic transcription
factors that also include c-MYC and MYCL. These proteins bind
DNA in a sequence specific manner in order to regulate normal
growth and differentiation during development [1]. The myc gene
family is only a subset of a much larger super family of genes that
encodes DNA binding basic helix-loop-helix proteins (bHLH).
Proteins containing the bHLH motif are known to be involved in a
diverse range of cellular processes including proliferation,
differentiation and morphogenesis. bHLH proteins can bind
DNA as homodimers, but heterodimerization with other bHLH
proteins has been shown to dramatically increase DNA binding
efficiency [2].
High level genomic amplification of the MYCN gene occurs in
approximately 20 to 25% of neuroblastoma (NB), a highly
genetically heterogeneous childhood cancer derived from precur-
sor cells of the sympathetic nervous system. MYCN amplification is
the single most important prognostic indicator of poor clinical
outcome [3]. Currently, patients with MYCN amplified neuroblas-
toma tumors have less than a 30% chance of 5-year survival, thus
identification of downstream MYCN targets is critically important
for the development of alternative treatment regimens and
improving patient survival.
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8154Analysis of gene expression in NB cell lines where MYCN levels
can be experimentally manipulated have identified many genes
and miRNA sequences whose expression is altered in response to
changes in MYCN levels [4–6]. Distinguishing direct versus
indirect effects based on expression profiling, however, is difficult
since MYCN regulates other transcription factors as well as
regulatory RNAs such as miRNAs. A number of studies have used
techniques such as chromatin immunoprecipitation (ChIP) to
experimentally confirm MYCN binding to the promoter regions of
specific genes [7–9], and more recent studies have identified
MYCN binding sites in proximity to miRNA promoter regions
[10]. Analysis of the relationship between MYCN binding and
expression of the target gene sequence, however, is not
straightforward, as MYCN binding throughout the genome is
far more ubiquitous than previously realized, with large numbers
of intergenic binding sites indicating a more general role for
MYCN in maintaining euchromatin structure that is independent
of its role in regulating the expression of specific genes [11].
Here, we have performed MYCN ChIP-chip studies on NB cell
lines using a set of microarrays containing all annotated human
gene promoter regions, as well as a custom tiling array covering
selected miRNA loci and intergenic regions. Assessment of E-box
usage and gene ontology enrichment analysis was carried out on
identified MYCN binding sites. Finally, using methylation
dependent immunoprecipitation (MeDIP), we also determine the
overall methylation status of MYCN binding sites and observed a
striking correlation between MYCN binding and DNA hyper-
methylation status in the neuroblastoma cell lines studied.
Results
To identify high confidence MYCN transcription factor binding
sites within promoter sequences across the genome, we performed
ChIP-chip using two antibodies that were reported in previous
MYCN ChIP-chip or ChIP-Seq studies, namely NCMII-100 [11]
and B84b [12,13]. Given that these mouse monoclonal antibodies
are raised against different epitopes of the MYCN protein, we
reasoned that MYCN binding sites identified independently by
both antibodies are more likely to be genuine. A pair-wise
comparison of log2 ratios from ChIP-chip experiments using the
NB cell line Kelly, revealed a good correlation across experiments
(R=0.8) between independent antibodies, confirming that this
approach was able to reproducibly detect MYCN binding sites
(Figure S1 A and B).
Characterisation of MYCN Transcription Factor Binding
Sites
ChIP-chip assays were performed on NB cell lines comprising a
MYCN amplified (Kelly), non MYCN amplified (SK-N-AS) and a
constitutively over-expressing MYCN cell line SHEP-21N which
contains a MYCN trans-gene under the control of a tetracycline
responsive repressor element [14] [referred hereafter as SHEP-
untreated (high levels of MYCN) and SHEP-treated (low
expression of MYCN), as illustrated in Figure S1 C and D]. A
number of previously reported MYCN targets were positive for
MYCN binding in our ChIP-chip experiments, confirming the
validity of our two antibody approach, including NME2 [13,15],
CRABP-II [16], ZNF259 [11], LIF [17] and members of the mini-
chromosome maintenance gene family [8]. Figure 1A illustrates
MYCN binding to one of these previously published positive
MYCN binding sites, NME2. Additional validation for the
enrichment of MYCN in the antibody precipitated fraction was
also obtained through qPCR based analysis of binding sites (Figure
S2). The level of enrichment (,2 to 4 fold) was similar to other
transcription factors such as ZNF217 [18] and other MYCN semi-
quantitative PCR validation experiments carried out by other
groups [11,13], consistent with the assertion that MYCN binds
with a weak affinity to promoter sequences.
Figure 1B summarises the total number of MYCN peaks
identified using the two independent MYCN antibodies and the
proportion of shared peaks across the respective cell lines analysed
using the NimbleGen 2-array promoter set. The total number of
MYCN peaks identified in the various cell lines was generally
consistent with the level of MYCN expression (Figure S1C–E).
The MYCN amplified (MNA) cell line Kelly displayed 1,142 more
positive MYCN peaks than the non-amplified cell line SK-N-AS,
while sharing 38% of MYCN peaks [Fig. 1B(i)]. In addition,
treating the SHEP cell line with doxycycline (dox) resulted in the
reduction of MYCN peaks by 52% [Fig. 1B(ii)]. This reduction in
the number of MYCN peaks is in contrast to a previous ChIP-chip
study using a similar knockdown strategy for MYCN which
observed a 99% decrease in the number of MYCN peaks [11];
however such differences in the decreased levels of MYCN binding
may be due to experimental variations in the ChIP design,
protocols and/or array designs used as well as the nature and
extent of the loci studied.
Interestingly, the percentage overlap of positive MYCN peaks
between Kelly and SHEP treated (20%) increased dramatically to
75% with MYCN over expression in SHEP untreated [Fig. 1B(iii
& iv)], confirming that the over expression of MYCN in the
SHEP-based system results in a binding pattern which has a high
degree of similarity to that of a MNA cell line such as Kelly. In
general, the low expressing MYCN cell lines (SK-N-AS & SHEP-
treated) displayed a similar number of MYCN peaks, although
when compared to each other only shared 25% of peaks
[Fig. 1B(v)]. The overlap of MYCN binding sites between NB
cell lines displayed in Figure 1B was found to be statistically
significant (P,0.001). This was determined using the expected
peak overlap frequency given the number of peaks retrieved in the
individual ChIP-chip experiments and the number of regions on
the microarray. Fisher’s Exact Test was then used to calculate the
P-value for each overlap based on the actual versus the expected
frequencies. ChIP-chip reactions performed with Dyna-beads only
and an isotype matched IgG mouse antibody using the 2-array
promoter set and/or custom tiled arrays resulted in only random,
minimal overlap with positive MYCN peaks (average overlap of
5.8%), indicating that the vast majority of the MYCN peaks were
not artifactually generated. In order to study the distribution of
MYCN binding around promoter sequences, identified peaks were
plotted in relation to the distance from their annotated
transcription start sites for the cell lines studied (Figure 2A). The
distribution of MYCN sites was generally consistent across cell
lines; however, upon treatment with dox the SHEP cell line
displayed an inward shift towards the transcriptional start site,
suggesting that both qualitative and quantitative changes in
MYCN binding occur upon dox treatment. Results confirm that
the majority of MYCN binding (average 80%) falls within 23kb to
+1kb of the transcriptional start site, which is consistent with
previous studies for MYCN and c-MYC [11,19].
E-box Usage in Neuroblastoma
E-box preference for putative MYCN binding within both the
MYCN amplified and non-amplified NB cell lines was assessed by
examining occurrences of all possible variants of the generic E-box
motif, CANNTG, within MYCN positive sites relative to the
background sequence on the promoter microarrays. Significance
was assessed using p-values derived from Fisher’s Exact test. For
this, we initially focussed on highly consistent MYCN binding sites
MYCN Binding in Neuroblastoma
PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8154Figure 1. MYCN ChIP-chip. (A) Identification of MYCN binding upstream of NME2. The scale across the top of the panel indicates the base pair
position on chromosome 17. Fluorescent intensity of probes from experiments using 2 independent MYCN antibodies around the NME2 promoter
are expressed as log2 ratios (green bars) and high confidence MYCN peaks (red bars) as identified by the NimbleScan peak finding algorithm. Position
of the NME2 transcript and the region tiled on the array are indicated by the bottom two panels. (B) Total number of MYCN peaks identified across
neuroblastoma cell lines. Venn diagrams (i–v) display the number of MYCN peaks which is shared and unique to each cell line. Statistical significance
of overlap for all comparisons was determined to be statistically significant (P,0.001) by Fisher’s Exact Test.
doi:10.1371/journal.pone.0008154.g001
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which were below the selected false discovery rate (FDR) threshold
in each cell line, were selected as the representative set of MYCN
binding sites and subjected to further examination (Table S1). As
illustrated in Figure 2B, the most significantly over-represented
motifs were CATGTG (p=0.0016) and CAACTG (p=0.032),
while the motif CATTTG (p=0.014) was significantly under-
represented. Next, we assessed if a shift occurred in E-box
preference between the MYCN-amplified state, in which MYCN is
highly expressed, and the non-amplified state, which would help
explain the mechanism of oncogenesis induced by MYCN
amplification. We examined the occurrence of the various E-box
motifs within MYCN binding sites that were found exclusively in
the MYCN amplified state. As displayed in Figure 2C, we observed
a significant enrichment of additional motifs CATTTG,
CATCTG, CAACTG, potentially indicating that MYCN binding
becomes less specific when it is highly abundant. A similar
enrichment was observed when plotting the frequency of E-box
motifs against raw fluorescent ratios in the Kelly (Figure 2D) and
SK-N-AS (Figure S3) NB cell lines.
Putative MYCN Function in Neuroblastoma
In order to identify sets of biological processes regulated by
MYCN, Gene Ontology (GO) analysis [20,21] was performed
using the subset of 265 sites common to all NB cell lines. A total of
270 genes map within a region 3 kb upstream and 1 kb
downstream of these 265 MYCN peaks. This group of genes
was significantly enriched for genes involved in mRNA transcrip-
tional regulation (n=121; p,0.005), particularly for KRAB box
transcription factors (n=84; p,0.002). KRAB-containing proteins
are thought to have critical functions in cell proliferation and
differentiation, apoptosis and neoplastic transformation [22]. In an
effort to determine the aberrant functions of MYCN within cell
lines containing the amplification, we generated a data set of genes
which were unique to the amplified cell line Kelly when compared
to the unamplified SK-N-AS. In a similar manner, we identified
genes which were unique to the over-expressing state of the SHEP
untreated cell line when compared to the dox treated, low-
expressing state.
Gene ontology analysis of genes unique to the MYCN over-
expressing states reveals statistically significant enrichment for genes
Figure 2. Distribution of MYCN transcription factor binding and E-box preference. (A) Percentage of MYCN binding sites around
transcription start sites. X-axis displays the distance in base pairs from UCSC annotated transcriptional start sites. Y-axis represents the percentage
frequency of positive MYCN binding sites identified in each neuroblastoma cell line. (B) Prevalence of E-box motifs within MYCN binding sites
detected by ChIP-chip across all cell lines and both antibodies. Statistically significant bars are indicated with their respective p-values (C) Prevalence
of E-box motifs within the MYCN binding sites detected by ChIP-chip in the MYCN-amplified state only. Statistically significant bars are indicated with
their respective p-values. (D) Association of E-box frequency with raw fluorescent ratios in MYCN binding sites on the promoter array which were
detected in the Kelly NB cell line. The number of E-boxes per kilobase (y-axis) is plotted against the raw array fluorescent ratio intensities.
doi:10.1371/journal.pone.0008154.g002
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mRNA transcriptional regulation (Kelly, p=1.18 E-17; SHEP
untreated, p=1.41 E-21), DNA helicases (Kelly, p=1.64 E-09;
SHEP untreated, p=3.22 E-05), Non-receptor serine/threonine
protein kinases (Kelly, p=4.33 E-07; SHEP untreated, p=3.72E-
18) and genes involved in G-protein mediated signalling (Kelly,
p=2.24 E-09; SHEP untreated, p=1.15 E-12), (Table S2). KEGG
pathway analysis revealed a shortlist of genes whose promoters
uniquely bound MYCN in the over expressing state and who are
members of established signalling pathways which are dysregulated
in cancer. Examples include members of the MAPK signaling
pathway, such as NRAS, a known oncogene; and members of the
WNT signaling pathway, DVL2, DVL3, APC and TCF7 which have
been previously implicated in colorectal and other cancers [23,24].
Co-Localization of MYCN Binding Sites and DNA
Hypermethylation
Increasing evidence for MYC family members having an
epigenetic role has been previously reported. This includes MYCN
exerting a more global effect on transcription by influencing states
of chromatin structure [11], as well as the recruitment of
methyltransferase DNMT3a to the c-MYC-MIZ1 complex [25].
In order to investigate further the epigenetic link of MYCN
function, we carried out methylation profiling of NB cell lines.
Hypermethylated DNA was isolated using the methylated DNA
immunoprecipitation method – MeDIP [26] and hybridised to a
commercial tiling array containing all UCSC annotated CpG
islands (28,226) and all known reference gene promoter regions
(Promoter Plus Arrays; NimbleGen). Regions shared across the
methylation CpG Island/promoter array and the ChIP two-array
promoter formats were extracted and used to compare the
association of hypermethylation peaks and MYCN TFBS peaks.
Regions of MYCN binding and DNA hypermethylation were
defined as ‘‘associated’’ only if their mapped genomic coordinates
directly overlapped. Table 1 displays the co-occurrence of MYCN
binding and DNA hypermethylation across cell lines. The co-
occurrence frequency is significantly higher than expected given
the individual background frequencies of MYCN binding and
hypermethylation in all NB cell lines examined. Furthermore we
observed similar E-box usage across both methylated and non-
methylated sites on promoter arrays. A pair-wise comparison of
SHEP treated and untreated log2 ratio methylation data displayed
a high degree of correlation (Figure S4; r=0.89), similar to that of
biological replicate experiments, indicating that DNA methylation
patterns remain relatively stable following the decrease in MYCN
levels in this cell line model.
To test whether the association of MYCN at sites of
hypermethylation is correlated with reduced expression of genes,
we have analyzed the Kelly and SK-N-AS cell lines using the
NimbleGen expression microarray platform. First, we determined
if hypermethylation in the absence of MYCN binding was
associated with reduced expression in our data set. A total of
360 genes were identified as differentially methylated between the
two cell lines (i.e. methylated in both replicates of one cell line, but
not in both replicates of the other) and did not have MYCN
binding. From this list, 218 genes were significantly differentially
expressed between the two cell lines (1.5 fold minimal difference;
Tables S3 and S4). Overall, hypermethylation correlated with
lower gene expression for the majority of genes in both Kelly and
SK-N-AS (p,0.001). Given that DNA methylation had a
significant impact on gene expression in our data set, we then
determined if MYCN binding at sites of hypermethylation had an
effect on gene expression. We identified 28 genes which were
exclusively hypermethylated and MYCN bound in Kelly com-
pared to SK-N-AS. In total, 16 genes displayed differential
expression, with 13 of these genes over expressed in Kelly
compared to SK-N-AS (p=0.01; 1.5 fold minimal difference;
Table S5). A further analysis identified 29 genes that were
hypermethylated in both Kelly and SK-N-AS which also had
MYCN binding in Kelly but not in SK-N-AS. Of these, 17 genes
were significantly differentially expressed between the two cell lines
(Table S6), with a significant bias towards over expression in Kelly
(15 up regulated and 2 down regulated; p=0.002).
The relationship between MYCN binding and hypermethylation
beyond promoter regions was also investigated using a custom tiling
array (see methods). As this array consists of non-discrete tiled
regions, the association of log2 ratios from MYCN ChIP-chip and
MeDIP-chip was evaluated using Pearson’s correlation and its
correspondingp-value.Results basedonthisanalysisconfirmedthat
the correlation between MYCN binding and DNA hypermethyla-
tion extended to intergenic regions tiled on the arrays (Table 2).
Selected methylated loci were confirmed by sequencing of bisulfite
treated DNA (Table S7). In order to determine if this association
occurs on the same copy of the chromosome we determined DNA
copy number status on each cell line using microarray-based
comparative genomic hybridisation (aCGH). Figure 3 displays the
co-localization of MYCN binding sites with sites of DNA
hypermethylation within a hemizygously deleted region on
chromosome 3 in SK-N-AS. The detailed panel 3B displays an
example of this combined MYCN/DNA hypermethylation analysis
across 100 kb of genomic sequence encompassing the let-7 g and
miR-135a-1 loci, illustrating the high correlation between MYCN
binding and sites of DNA hypermethylation. Reverse transcriptase
qPCR assays indicated that both of the miRNAs shown in Figure 3
are expressed in SK-N-AS (data not shown). However, the
relationship of the identified peaks of hypermethylation/MYCN
binding with expression is complicated by the fact that very little is
Table 1. Association of MYCN transcription factor binding sites and hypermethylated regions in gene promoters.
NB cell
line
No. MYCN
binding
sites
No. hyper-
methylated
regions
No. MYCN and
Hypermethylated
regions
MYCN and
Hypermethylated
regions (%)
No. MYCN
and Non-
methylated
MYCN and
Non-methylated
(%)
Observed
freq Expected P-value
Kelly 960 804 188 19% 772 81% 0.009 0.002 ,1e-16
SK-N-AS 640 924 120 19% 520 81% 0.006 0.001 ,1e-16
SHEP
DOX+
791 1235 215 27% 576 72% 0.010 0.002 ,1e-16
SHEP
DOX-
1313 1913 418 31% 895 67% 0.020 0.006 ,1e-16
doi:10.1371/journal.pone.0008154.t001
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which have reported on this subject, only Marson et al. [28] have
reported a putative miRNA promoter region for mir-135a (chr3:
52307870-52308065) and 2 studies (Marson & Ozsolak et al.)
[28,29] have identified a putative let-7g promoter (region common
to both studies; chr3:52207870-5230865). Both putative miRNA
promoter regions fall outside of our identified peaks of hypermethy-
lationand MYCN bindingin SK-N-AS. The transcriptional control
of let-7g is further complicated by the fact that it is present within
the second intron of the WDR82 gene.
Discussion
The MYCN oncogene was originally identified due to its
frequent amplification and over expression in certain tumours,
chiefly human neuroblastoma [31,32]. In this study, we have
identified and analysed high confidence MYCN binding sites using
ChIP-chip assays based on two independent antibodies to gain an
insight into the binding patterns and possible functions of MYCN.
As far as we are aware, this conservative strategy has not been
applied to ChIP-chip analysis of other transcription factors.
MYCN Exhibits Significant Selection of the CATGTG/
CACATG E-box Motif
It has previously been reported that both c-MYC and MYCN
bHLH transcription factors bind to the canonical E-box motif
CAC(A/G)TG [33-36]. More recent studies have suggested that c-
MYC exhibits a significant preference for CACGTG and a
negative selection for CATGTG [37]. Our results indicate that
MYCN exhibits greater E-box selectivity for the CATGTG motif
in NB cell lines than for the classic CACGTG motif. Interestingly,
in a recent MYCN ChIP analysis of the LIF promoter, which
contains both CACGTG and CATGTG, exclusion of the
CATGTG sequence resulted in a significant reduction of MYCN
binding in-vitro [17]. The greater affinity of MYCN for CATGTG
appears to occur in both MYCN amplified and non-amplified
cells. Our findings are also consistent with the analysis of genes
which are differentially expressed in response to MYCN over
expression in NB cell lines, where the CATGTG motif was
identified in the promoter regions of 95/139 differentially
expressed genes (68%) compared to the CACGTG motif which
was detected in promoter regions of 41/139 genes (29%) [4]. In
contrast to our results, Cottermann et al previously reported a
statistically significant over representation for the CACGTG E-
box only [11]. However, this study varied in its experimental
approach (e.g., use of one antibody, microarray design and data
analysis parameters) and the reported enrichment analysis was
based on a comparison between the presence of the CACGTG
motif and all other E-box variants grouped together as CANNTG.
Differences in reported E-box frequencies between both studies
may therefore exist as we analysed each distinct class of E-box
within the CANNTG group. This approach avoided any possible
masking effect which an under represented E-box (CATTTG,
Figure 2B) might have over a significantly over represented E-box
(CAACTG, Figure 2B) within the CANNTG group.
In-vitro analyses have previously demonstrated the binding of c-
MYC to cis-acting canonical E-boxes CACGTG and CATGTG
[36] as well as non-canonical variants. Later ChIP-seq in-vivo
analysis indicated that c-MYC bound to both forms in B-cells [19]
and that the CACGTG was predominant in HeLa cells. Previous
evidence indicates some E-box preference in the MYC family
where Kim et al. demonstrated that although CACGTG is
enriched, an increase in Myc binding to promoters that contain
each of the previously defined E-box sequences, except CATGTG
was observed [37].
From the functional perspective, Westermann et al. [13] reported
an inverse relationship between MYCN and c-MYC expression in
different neuroblastoma tumor subtypes, where c-MYC was
expressed at higher levels in MYCN single copy high risk tumors
relative to MYCN amplified or MYCN single copy low risk tumors.
Although this finding indicated a potential redundancy for the
functions of these genes in tumorigenesis, the authors also
demonstrated that a significant number of MYCN/c-MYC target
genes are less responsive to MYCN than to c-MYC and also that a
subgroup of genes were repressed by MYCN but not by c-MYC.
Our results, highlighting differences in E-box selection between
MYCN and c-MYC would indicate that these transcription factors
should not be completely functionally redundant in cancer. The
differences in E-box usage also have relevance to the role of these
genes in normal developmental processes. Both proteins clearly play
distinct roles in development since homozygous null c-Myc and
MYCN mice die at about embryonic days 10 and 12, respectively.
Whenmycnisinserted intothec-myc locusinmice,itisexpressedand
regulated similarly to c-myc during development and to a great
degree restores normal development to c-myc homozygous null
mice [38]. However, non-redundancy is evidenced by the fact that
these mice are significantly smaller and in some cases display
dystrophy of skeletal muscle. This evidence suggests that although
mycn and c-myc share some functional roles, mycn cannot
completely replace all functions of c-myc even when similarly
regulated. The fact that these proteins share only 32% amino acid
sequence similarity [39] is another good indication that they should
not be completely functionally redundant. Tissue specific condi-
tional mycn knockout in neural progenitor cells during mouse
development has demonstrated the importance of mycn for
regulating neurogenesis [40], perhaps explaining the greater role
of MYCN in neuroblastoma pathogenesis over c-MYC.
Potential Oncogenic Functions of MYCN in the Amplified
State
Amplification of the MYCN locus (up to 200 copies) in NB
leads to increased protein production and based on our results,
Table 2. Association of MYCN transcription factor binding sites and hypermethylated regions in inter/intragenic regions.
NB cell line
No. MYCN
binding sites
No. hypermethylated
regions
No. MYCN and
Hypermethylated
regions
MYCN and
Hypermethylated
regions (%)
Pearson’s
correlation (r)o f
log2 ratios P-value
SK-N-AS 638 3148 487 76% 0.608 P,10e-16
SHEP DOX+ 411 2982 260 63% 0.535 P,10e-16
SHEP DOX- 1188 3089 677 57% 0.503 P,10e-16
doi:10.1371/journal.pone.0008154.t002
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regions in Kelly compared to the MYCN unamplified cell line SK-
N-AS. Gene ontology analysis of targets which are uniquely
bound by MYCN in the over expressing state revealed
enrichment for DNA helicases and mRNA transcriptional
regulation, amongst others. It has been previously shown that
Figure 3. Association of MYCN binding and DNA hypermethylation around the let 7g and miR-135a-1 locus in SK-N-AS NB cell line.
(A) Array-CGH profile of chromosome 3p displaying a large 60.5 Mb terminal deletion in SK-N-AS. (B) Detailed view of the hemizygously deleted let-
7 g/miR135a-1 locus. The upper two panels display the MYCN ChIP-chip raw log2 ratios and identified peaks for both MYCN antibodies (NCMII-100
and B84b). Red and orange peaks represent regions of enrichment with an FDR of ,0.05 and 0.05–0.1, respectively. MeDIP results for SK-N-AS are
displayed in the lower panels in blue, which include log2 ratios of MeDIP/Input, Kolmogorov-Smirnov test p-values (2log10) and the merged
statistically significant peaks of hypermethylation across the region. The position of CpG islands and orientation of miRNAs are displayed in the two
bottom panels.
doi:10.1371/journal.pone.0008154.g003
MYCN Binding in Neuroblastoma
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the promoter regions of the minichromosome maintanence
complex genes (MCM), resulting in increased expression [8].
The MCM protein family function as DNA helicases which are
critical for DNA synthesis, play a significant role in various aspects
of genome stability [41,42] and are dysregulated in numerous
cancer types [43–46]. However, the role of the specific MYCN
positive DNA helicases and other functional groups identified
remains the subject of further study.
A more focused KEGG pathway analysis of our data indicates
that MYCN binds upstream to a number of genes in the WNT
signalling pathway. Dysregulation of genes associated with the
WNT/b-Catenin pathway has been previously reported in a
cohort of 73 primary NB tumours [47]. Interestingly, differential
expression of genes within the pathway was identified between
MNA and high-stage non-MNA subtypes. In our data, DVL2,
DVL3, APC and TCF7 were identified as bound by MYCN only
in the over expressing state (Kelly and SHEP untreated).
However, these targets must be further functionally tested to
evaluate the influence of MYCN on this pathway. Finally,
additional genes which were identified from our MYCN binding
analysis have also been recently reported by Vermeulen et al. [48]
as part of a 59-gene expression signature which was applied as an
accurate predictor of clinical outcome in patients with neuro-
blastoma. Although multivariate logistic regression analysis
showed that the signature was independently statistically
significant in a model adjusted for MYCN status and other
predictors of prognosis, we have determined that a number of
these genes including PTN and CPSG3, have positive MYCN
b i n d i n gs i t e su p s t r e a ms u g g e s t i n gt h a tM Y C Nm a yp l a yap a r ti n
the control of these genes.
Based on the analysis of E-box usage in the MYCN amplified
state, we hypothesize that over expression of MYCN in the
amplified state may lead to aberrant binding to additional
weaker affinity E-box motifs such as CATTTG, CATCTG and
CAACTG. One striking observati o nw h e nc o m p a r i n gt h eE - b o x
usage of MYCN targets in the unamplified compared to the
amplified state was that one motif, CATTTG, switched from
being statistically underrepresented in the unamplified state
(p=0.014) to statistically significantly over represented in the
amplified state (p=0.023). Interestingly, a bHLH transcription
factor which is phylogenetically related to MYC, microphthal-
mia-associated transcription factor (MITF) [49], binds the classic
E-box motif CACGTG as well as CATTTG [50-52]. MITF,
which is not expressed in NB cells [53], has been shown to have a
role in the regulation of melanocyte development and is similar
to MYCN in that it is a reported oncogene which is amplified in
cancer [54]. It may be possible that an excess of MYCN in
MYCN amplified NB leads to weak aberrant binding at
unoccupied CATTTG sites potentially deregulating the expres-
sion of MITF or other bHLH targets in NB cells, thus promoting
tumorigenesis.
Associated MYCN and Hypermethylated Loci
Utilizing a combined genome-wide ChIP-chip/MeDIP-chip
approach we demonstrated that MYCN binding is highly enriched
in genomic regions of DNA hypermethylation and that enrich-
ment of this co-localization is prominent within intra- and
intergenic regions in addition to promoter sequences. Previous
promoter based in-silico analysis of hypermethylated DNA
sequences has demonstrated enrichment for specific transcription
factors [55]. The non-random association of MYCN binding with
DNA hypermethylated sequences might be explained through the
previous observation that c-MYC can recruit the DNA methy-
transferase DNMT3a to the promoter region of genes to induce
gene silencing [25]. Brenner et al. [25] determined that there was a
synergistic repressive effect on the promoter of p21, when both c-
MYC and DNMT3a were co-transfected into U2OS cells. The
model involved c-MYC binding to the cofactor MIZ to form a
ternary complex with DNMT3a at the promoter of p21, inducing
methylation. Although, structural differences exist between c-
MYC and MYCN within the N-terminal domain, both proteins
contain the MBI and MBII domains which are required to
associate with DNMT3a [25,56], indicating that MYCN could
interact in a similar manner.
Interestingly, Perini et al. [12] demonstrated that methylation of
the CpG dinucleotide within the CACGTG E-box prevents
MYCN binding to a number of gene promoters [12]. Our results
showing preferential association of MYCN to sites that are
hypermethylated are not inconsistent with Perini et al. since our
array results are not of sufficient resolution to ascertain the
methylation status of specific base pairs. In addition, analysis of E-
box motifs confirmed that there was no significant difference in the
E-box usage of the classical CACGTG in methylated compared to
non-methylated sites, which one would expect if this sequence was
predominantly utilised by MYCN. It is also possible that in many
instances MYCN is not binding directly to DNA sequences, but
instead is interacting with another DNA binding partner, such as a
methyl binding protein.
Through the integration of DNA copy number, MeDIP-chip
and MYCN ChIP-chip data for the same NB cell lines we have
identified overlapping regions of hypermethylated DNA and
MYCN binding within hemizygously deleted chromosomal
regions, thus confirming that this association occurs on the same
allele. Previously, Cotterman et al. [11] determined that MYCN is
a weak transcription factor even at genes which it directly binds
and found that overall changes in the expression of MYCN bound
genes were modest, most often in the range of 2-fold or less despite
profound chromatin modification changes. Based on our expres-
sion analysis of methylated genes, we confirmed that differentially
hypermethylated genes correlated with lower expression in both
NB cell lines studied. Surprisingly, upon integrating the MYCN
ChIP-chip, methylation and expression data, we discovered that
genes which are MYCN bound and hypermethylated tend to have
increased expression compared to genes which are methylated/not
MYCN bound or not methylated/not MYCN bound. The
association of MYCN with higher expression of methylated
promoter regions although interesting, requires further experi-
mentation to determine if there is an actual cause and effect
relationship. In addition, other factors such as differences in
miRNA expression profiles could also be influencing gene
expression.
It has also been reported that MYCN has a much more global
role in the regulation of transcription and chromatin than
previously anticipated and that it is required to maintain
euchromatin in a wide spread manner, including at intergenic
sites [11,57]. When analysed, the association of putative MYCN
binding sites within inter- and intragenic regions was more
prominent than that observed at annotated classical promoter
sequences, possibly supporting its role as a more global mediator of
chromatin modification. Our results further support a possible
dual role for MYCN and DNA hypermethylation, namely that of a
classical transcriptional repressor of upstream genes and that of a
mediator of global chromatin structure. A future aspect which
should be considered is a more comprehensive analysis of MeDIP,
MYCN ChIP-chip and other possible co-factors such as
DNMT3a, using sets of higher density whole genome arrays or
a next generation sequencing platform.
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Western Blot
Total cell lysate and nuclear extractions were prepared from the
cultured neuroblastoma cell lines SHEP-21N, Kelly and SK-N-
AS. These lysates were added to Laemmlibuffer, electrophoresed
in a 10% SDS-PAGE gel and transferred to a nitrocellulose
membrane. After blocking overnight with milk protein, the blots
were probed with either a 1 in 500 dilution of NCMII-100
(ab16898; Abcam) or B84b (sc-53993; Santa Cruz Biotechnology)
antibodies, followed by a 1 in 2000 dilution of secondary rabbit
anti-mouse IgG antibody (ab6728-1; Abcam). The specificity of
the antibodies for MYCN was confirmed and blots were then
stripped and reprobed using a 1 in 2000 dilution of mouse anti-
GAPDH antibody (Ab9484; Abcam). The expression of MYCN
was detected in all cell lines (Figure S1C–E).
Cell Culture
SHEP-21N Cells were obtained from Dr Louis Chesler with the
permission of Prof. Manfred Swab. The Kelly and SK-N-AS cell
lines were obtained from the European Collection of Animal Cell
Cultures (Porton Down, United Kingdom). SK-N-AS cells were
grown in EMEM supplemented with 1% non-essential amino
acids, 2 mM L-glutamine, 10% fetal bovine serum and penicillin/
streptomycin. Kelly cells were cultured in RPMI-1640 supple-
mented with 2 mM L-glutamine, 10% fetal bovine serum and
penicillin/streptomycin. SHEP-21N cells were grown in RPMI
1640 with 2 mM L-glutamine, penicillin/streptomycin and 10%
tetracycline-free fetal bovine serum (HYC-001-333C, Fisher
Scientific) In order to abrogate the expression of MYCN in the
SHEP-21N cell line, the cells were maintained in their growth
media supplemented with 50ng/ml Doxycycline (8634-1, Clon-
tech). Cells were cultured using Hyperflask cell culture vessels
(#10010, Corning) for six days. All cell culture reagents were
obtained from GIBCO unless otherwise stated.
ChIP-Chip Analysis
ChIP assays were performed using the above antibodies
according to the standard NimbleGen ChIP protocol. Briefly,
1610
9 cells were fixed with 1% formaldehyde solution for 10 min
on ice, centrifuged and rinsed with ice-cold PBS. Cell nuclei were
isolated and sonicated to generate DNA fragments of approxi-
mately 1 kb in length. The resulting fragmented chromatin was
aliquoted into 2 mg/ml stocks and stored at 280uC. One 2 mg/
ml aliquot was used per ChIP reaction. DNA was enriched by
immunoprecipitation using 10 mg of either the B8.4.B or NCMII-
100 anti-MYCN antibodies complexed to M-280 Sheep anti-
Mouse Dynabeads (112-02D, Invitrogen). The formaldehyde
crosslinks, protein and RNA was removed from the immunopre-
cipitated DNA sample through heat denaturing, proteinase K and
RNase A treatments. An un-enriched sample of DNA was treated
in a similar manner to serve as input. ChIP and input DNA was
fluorescently labelled using Klenow fragment (M0212M, New
England Biolabs) and Cy5/Cy3 random primers (N46-0001-50/
N46-0002-50, TriLink BioTechnologies). The Cy5-ChIP and
Cy3-input labelled DNA samples were co-hybridized to micro-
arrays for 18 hours, post hybridisation washes were carried out
and microarrays were scanned using an Axon 4000B microarray
scanner with GenePix 6.0 (Molecular Devices). Microarrays used
included the HG18 two-Array Promoter Set and a custom miRNA
array manufactured by Roche NimbleGen. The promoter arrays
include an average coverage of 4.7 kb around promoters for all
RefSeq genes, UCSC known genes and the Mammalian Gene
Collection. A custom array was designed to include tiled sequence
of 50 kb 59 and 20 kb 39 of 528 miRNAs. Image files generated
after scanning were analyzed using NimbleScan Software Version
2.4. Sites of enrichment were identified using the normalised log2
ratios and the NimbleScan peak finding function. The in-built
peak analysis algorithm detects significantly enriched regions that
have at least 4 probes above a threshold value of log 2.0, identifies
them as ‘‘peaks’’ and assigns a false discovery rate (FDR). An FDR
value of 0.1 was used in the initial screening of peaks from
individual experiments for both NCMII-100 and B84b antibodies.
Peaks with an FDR of less than 0.1 which were shared across ChIP
reactions using both MYCN antibodies were filtered using an in-
house Java application. This produced a final set of consistently
bound high confidence regions for each of the cell lines used in the
study. This final set of high confidence peaks was subsequently
used in further transcription factor binding site and Gene
Ontology analysis.
Transcription Factor Binding Site Analysis
DNA sequence data for the processed ChIP regions for each cell
line were retrieved from the UCSC database [58]. Phylogeneti-
cally conserved sequence between Human (Hg18) and Mouse was
selected for motif analysis. E-box specificity was assessed by
examining the occurrence of the various forms of E-boxes
conforming to the generic CANNTG motif. When counting E-
box motifs within the ChIP derived putative MYCN binding sites,
both the forward and reverse of each motif was taken into account.
If this were not the case palindromic sequences such as CACGTG
would be artificially over-represented with respect to other motifs.
The sequence present on the promoter array was used to assess the
background frequency of each E-box motif. In order to assess over
or under-representation within ChIP sequences it is also essential
to take into account the lengths of the ChIP sequences. For
example, if the average length of a ChIP pull-down is 550 bp this
window must also be used when performing a random background
count of this motif. Significance for over (or under) -representation
was assessed using P-values based on Fisher’s Exact test when
compared to background motif frequency.
Gene Ontology Analysis
Gene Ontology analysis was carried out using the DAVID
Functional Annotation Tool [20,21]. In all analysis the following
parameters were used - Functional enrichment was assessed using
the Panther Biological Process and Molecular Function and
KEGG Pathway databases. A custom Java based application was
used to identify common and unique peaks of enrichment across
cell lines and the resulting gene Entrez IDs were submitted to
DAVID. Significance of over-representation of functional catego-
ries was assessed via Fisher’s exact test and corrected for multiple
comparisons using the Bonferroni method. After analysis, all
categories with a p value greater than 0.001 and which represented
less than 5% of the total number of genes was eliminated.
Redundant and non-informative terms (eg. Other Metabolic
Pathways) were also excluded.
Q-PCR Analysis
Taqman Probes were designed and manufactured by Applied
Biosystems against regions of enrichment identified for the ChIP-
chip experiments. A negative control probe was also designed
against un-enriched genomic regions for comparison. Q-PCR
analysis was performed on immunoprecipitated and un-enriched
input DNA samples in duplicate. The relative level of enrichment
(RQ) was calculated for each of the target regions using the
comparative Ct method. Details of primer and probe sequences
are provided in Table S8.
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The protocol used was as previously described by Weber et al.
[26]. Briefly, five micrograms of DNA was fragmented by
sonication to 400–800 bp in size and confirmed by running
100 ng on a 2% agarose gel. Four micrograms of the sonicated
DNA was incubated overnight with an anti-59 methyl-cytidine
antibody (BI-MECY-1000; Eurogentec). A Taqman quality
control qPCR assay was performed to detect the relative fold
change of enrichment of the methylated H19 locus relative to an
unmethylated H3B [59], prior to microarray hybridization (Figure
S5). The MeDIP DNA and reference control were differentially
labelled using Cy5 and Cy3 respectively, and co-hybridised to a
custom miRNA array and the CpG Island promoter plus array
from Roche NimbleGen. The 385,000 probe CpG Island Plus
Promoter Array includes all UCSC-annotated CpG islands, 1 kb
tiled sequence around all RefSeq gene promoter regions and DNA
methylation positive control regions (HoxA, H19/IGF2, KCNQ1
clusters). Arrays were scanned using the GenePix 4000B scanner
and the following analysis was performed using the Nimblescan
Software Version 2.4: normalised log2 ratio data was calculated
and a one-sided Kolmogorov-Smirnov test (KS; using a sliding
window of 750 bp) was applied to determine whether the probes
were drawn from a significantly more positive distribution of
intensity log-ratios than those on the rest of the microarray. The
resulting score for each probe was the -log10 p-value from the
windowed KS test around that probe. Hypermethylated peaks
were detected by searching for at least 2 probes above a p-value
minimum cut off (2log10 of 2) and peaks within 500 bp of each
other are merged. Resulting data files were visualised using
SignalMap 1.9. Experiments were performed in duplicate. Pair-
wise comparison of cell line replicates resulted in high correlation
co-efficients [r=0.82 (Kelly) and 0.89 (SK-N-AS); Figure S6].
Peaks only detected in both experiments were used for further
analysis.
Bisulphite Sequencing
A total of 500 ng of DNA from Kelly and SK-N-AS was
bisulphite converted using the EZ DNA-methylation Gold kit (Cat.
No. D5005 & D5006, Zymo) using the alternative conversion
reaction 2 as per manufacturer’s instructions. The converted DNA
was subsequently purified in 50 ml of elution buffer. PCR primers
were designed using methyl primer express (www.appliedbiosys-
tems.com/methylprimerexpress). PCR was carried out using
AmpliTaq Gold mastermix (Cat.No. 4326717, Applied biosys-
tems) under the following conditions: 95uC for 10 min; 94uC for
30 sec, 58–60uC for 30 sec, 72uC for 30 sec (35 cycles) followed by
72uC for 10 min. The PCR product was resolved on a 1.5%
agarose gel with SYBR-safe. Twenty microlitres of PCR product
was subsequently purified using ExoSAP-IT (Cat No. 78200,
USB) and QIAquick PCR purification kit (Cat. No. 28104,
Qiagen), as per manufacturer’s instructions. Purified PCR product
was further sequenced in the forward and reverse direction at
MWG biotech. Resulting electropherograms were analyzed using
the BIQ analyzer [60].
Array-CGH Analysis
Array CGH was carried out as previously described [61] using a
385,000 feature array from NimbleGen.
Gene Expression Analysis
Total RNA was extracted from Kelly and SK-N-AS using the
RNeasy Mini kit (Cat. No. 74104, as per manufacturer’s
instructions QIAGEN), including on-column digestion of DNA
using the RNase-Free DNase Set (Cat. No. 79254, QIAGEN), to
ensure complete DNA removal. RNA integrity was confirmed
using the Experion RNA StdSens Analysis Kit (Cat. No. 700-
7103, Bio-Rad). The ExpressArt TR Micro Kit (Cat. No. 6199-
A30, AmpTec) was used to synthesise double-stranded cDNA
from 3 ug total RNA, which was subsequently used to generate
amplified amino-allyl antisense RNA (aRNA) using the Super-
Script Indirect RNA Amplification System (Cat. No. L1016-01,
Invitrogen). The aRNA was coupled to Cy3 reactive dye (Cat.
No. 25-8010-79, Amersham Biosciences). Four micrograms of
Cy3-aRNA was hybridised to the Homo sapiens 4x72K Gene
Expression Array from Roche NimbleGen (Cat. No. A4487001-
00-01), as per manufacturer’s instructions. Arrays were scanned
using the GenePix 4000B scanner and gene expression data
analysis was performed using NimbleScan Software Version 2.4.
Supporting Information
Figure S1 Performance of MYCN ChIP-chip antibodies. (A &
B) Pair-wise comparison of log2 ratio between two different
antibodies used for the ChIP reactions on microarrays containing
promoter regions from chromosome 1 to 10p (A) and chromosome
10q to Y (B). An average value over 4 probes was used for plotting,
consistent with the peak finding analysis software criteria. Pearson
correlations (r) is displayed at the top right of each panel. (C)
Western blot of Kelly and SHEP nuclear extracts using the
MYCN antibody NCMII-100, (D) Western blot of Kelly and
SHEP and SK-N-AS nuclear extracts using the MYCN antibody
B84b. (E) Western blot of SK-N-AS using both MYCN antibodies.
Blots were reprobed for GAPDH which confirmed even loading
across wells.
Found at: doi:10.1371/journal.pone.0008154.s001 (0.73 MB TIF)
Figure S2 PCR validation of MYCN ChIP reactions. qPCR
validation of positive MYCN transcription factor binding sites.
Fold enrichment of positive MYCN target sites is displayed.
Experiments were carried out in duplicate using the delta-delta Ct
method and results are plotted relative to a negative MYCN
binding region (SEMA3B) identified on the arrays and set to 1.0.
Found at: doi:10.1371/journal.pone.0008154.s002 (0.31 MB TIF)
Figure S3 Association of E-box frequency to raw fluorescent
ratios in SK-N-AS. Y-axis represents the E-box frequency per
kilobase, while the x-axis indicates the florescent intensity ratios.
Found at: doi:10.1371/journal.pone.0008154.s003 (0.08 MB TIF)
Figure S4 Pair-wise comparison of MeDIP log2 ratios between
SHEP treated and untreated cell lines. An average value over 4
probes was used for plotting. Pearson correlations (r) is displayed at
the top of the panel.
Found at: doi:10.1371/journal.pone.0008154.s004 (0.21 MB TIF)
Figure S5 qPCR enrichment of MeDIP reactions. Graph
displays fold enrichment for Kelly and SK-N-AS using the Ct
method for the imprinted H19 locus versus a non-methylated H3B
promoter following immunoprecipitation with an anti-methyl
cytidine antibody, as used by Weber et al. [59]. A negative
control MeDIP reaction using an isotype matched normal mouse
IgG antibody is also displayed. PCR reactions were performed in
duplicate.
Found at: doi:10.1371/journal.pone.0008154.s005 (3.18 MB TIF)
Figure S6 Pair-wise comparison of MeDIP log2 ratios between
NB cell line replicates. (A) Kelly and (B) SK-N-AS pair-wise
comparison plots. An average value over 4 probes was used for
plotting. Pearson correlations is displayed at the top of the panel.
Found at: doi:10.1371/journal.pone.0008154.s006 (0.49 MB TIF)
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Found at: doi:10.1371/journal.pone.0008154.s007 (0.09 MB
PDF)
Table S2 Gene ontology of MYCN target genes.
Found at: doi:10.1371/journal.pone.0008154.s008 (0.07 MB
PDF)
Table S3 Expression of genes (fold change ,0.5 and .1.5)
which are methylated in SK-N-AS and not methylated in Kelly.
Found at: doi:10.1371/journal.pone.0008154.s009 (0.07 MB
PDF)
Table S4 Expression of genes (fold change ,0.5 and .1.5)
which are methylated in Kelly and not methylated in SK-N-AS.
Found at: doi:10.1371/journal.pone.0008154.s010 (0.07 MB
PDF)
Table S5 Expression of genes (fold change ,0.5 and .1.5)
which are methylated and MYCN bound in Kelly and not
methylated or MYCN bound in SK-N-AS.
Found at: doi:10.1371/journal.pone.0008154.s011 (0.04 MB
PDF)
Table S6 Expression of genes (fold change ,0.5 and .1.5)
which are methylated and MYCN bound in Kelly and methylated
but not MYCN bound in SK-N-AS.
Found at: doi:10.1371/journal.pone.0008154.s012 (0.03 MB
PDF)
Table S7 Bi-sulphite sequencing of selected loci.
Found at: doi:10.1371/journal.pone.0008154.s013 (0.01 MB
PDF)
Table S8 Taqman q-PCR primer and probes.
Found at: doi:10.1371/journal.pone.0008154.s014 (0.06 MB
PDF)
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